Research Library
Metabolic Research• Beginner
What is retatrutide?
Answer
Retatrutide (LY3437943) is an investigational synthetic peptide and single-molecule agonist of the GIP, GLP-1, and glucagon receptors. It remains unapproved and is being evaluated in clinical trials.
Detailed Explanation
Retatrutide is described as a triple hormone receptor agonist because one molecule activates GIP, GLP-1, and glucagon receptors. Researchers are studying how coordinated activity across these signaling systems affects metabolic outcomes. As of July 2026, retatrutide has not been approved by the FDA or any other regulatory agency. Lilly states that human access is limited to its sponsored clinical trials. PepMarket information and products are for laboratory research only and are not for human or veterinary use.